

Aylin Toplu\*, Berna Özen, Zeynep Us, Nazım Haspolat, M. Zafer Gören

Marmara University, Department of Medical Pharmacology, School of Medicine, Istanbul, Turkey

## INTRODUCTIONS

Anti-TNF drugs like adalimumab, infliximab, certolizumab, golimumab, and etanercept are immunological agents that are frequently used for rheumatological diseases. Limited data of the teratogenicity of anti-TNF drugs is available.

We aimed to show the pregnancy outcomes of the pregnant women who admitted to Marmara University Teratology Information Service between 2012-2022.

## METHODS

We phoned patients who were exposed to anti-TNF drugs during pregnancy and had visited our clinic between 2012-2022. Our evaluation focused on the duration of drug exposure, the occurrence of complications, the management of chronic diseases during pregnancy, and the outcomes.

## RESULTS-Infliximab

Six pregnant women exposed to Infliximab and cases			
Patient-1	Patient-2	Patient-3	Patient-4
<ul style="list-style-type: none"> <li>ICU for neonatal asphyxia</li> </ul>	<ul style="list-style-type: none"> <li>Curettage at 6 weeks due to chronic disease risk</li> </ul>	<ul style="list-style-type: none"> <li>Low birth weight and a baby was ICU hospitalized</li> </ul>	<ul style="list-style-type: none"> <li>ICU for 10 days due to neonatal urinary tract infection</li> </ul>

## RESULTS-Adalimumab

Eleven pregnant women exposed to adalimumab (Mean age:33)	Gestational conditions	The other case
	<ul style="list-style-type: none"> <li>Five spontaneous abortions (2 of them from disease exacerbation)</li> </ul>	<ul style="list-style-type: none"> <li>One infant showed premature closure of the anterior fontanel at 4 months.</li> </ul>

## RESULTS-Etanercept,golimumab

This study included 7 pregnant women exposed to etanercept and 4 exposed to golimumab, with a mean age of 36 (ranging from 29 to 42). None of the infants born to these women had congenital abnormalities. One pregnant woman exposed to both isoniazid and golimumab during the first 4 weeks of pregnancy experienced abortion.

## RESULTS-Certolizumab

Sixteen pregnancies exposed to certolizumab, with a median exposure period of 27 weeks (range: 4-38 weeks). Notably, one child was hospitalized for dyspnea at three months of age.

## CONCLUSIONS

While we lack age- and year-matched controls, it is crucial to highlight the significance of reporting outcomes related to anti-TNF-alpha drug exposures. Our findings indicate a higher miscarriage rate associated with adalimumab use, but additional studies are needed to confirm these results.

## References

- Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of anti-rheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis*. 2016 May;75(5):795-810.
- Mariette X, Forger F, Abraham B, Flynn Ad, Molto A, Flipo RM, van Tubergen A, Shaughnessy, Simpson J, Teil M, Helm E, Wang M, Chakravarty EF. 2018. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Ann Rheum Dis* 77(2): 228-233.
- Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. *Clin Dev Immunol*. 2012;2012:985646
- Bertrand K, Rossi S, Wells A, Best B, Chambers CD. 2022. The concentration of etanercept in human milk and infant outcomes. *J Rheumatol* PMID: 36379569.
- Simponi (Golimumab) Injection: Drug Approval Package. Pharmacology review, part 1 (mouse) and part (monkey)